Agentic AI is moving life sciences beyond task automation
Agentic AI is moving life sciences beyond task automation into coordinated, context-aware workflows that can plan, execute, escalate, and adapt across clinical, regulatory, quality, manufacturing, and commercial operations.
For biotech and pharma leaders, the opportunity is not “AI everywhere.” It is targeted, governed automation that accelerates high-value workflows while preserving human oversight, data integrity, validation evidence, and regulatory accountability.
This white paper shows how agentic AI and intelligent workflows can drive measurable outcomes in regulated environments — without pretending that a clever chatbot is an operating model. Standards, mercifully, remain a thing.
What's inside
- Identify high-value AI workflows: understand where agentic AI can support clinical trials, safety monitoring, regulatory compliance, and operational decision-making.
- Quantify business impact: evaluate opportunities to reduce trial costs, accelerate submissions, improve processing speed, and reduce compliance errors.
- Govern AI in regulated environments: balance innovation with risk management, human oversight, validation strategy, and change control.
- Move from pilots to scale: build the roadmap, data governance, and adoption model needed for durable intelligent workflow transformation.
Why agentic AI changes the workflow conversation
Traditional automation follows predefined rules. Agentic AI can interpret context, coordinate steps, recommend next actions, trigger supporting workflows, and keep humans in the loop when judgment or approval is required. That makes it especially powerful in fragmented life sciences processes where data, evidence, and accountability live across many systems.
The payoff is real only when teams design around regulated work: intended use, data provenance, access controls, decision rights, audit trails, model oversight, and validated change. In other words, the agent must fit the quality system — not the other way around. Mature programs anchor that work in deliberate AI governance and compliance so every AI-assisted step stays explainable and inspection-ready.
KPIs to measure agentic workflow value
Track both productivity and control performance. If AI makes work faster but less explainable, the program is borrowing trouble with interest.
What the white paper covers
- How agentic AI is reshaping life sciences: faster clinical trials, predictive safety monitoring, regulatory workflow support, and human-supervised automation.
- Business impact of AI-driven workflows: cost, speed, compliance, and time-to-market opportunities when automation is targeted and governed.
- Adoption challenges in regulated environments: data governance, risk mitigation, validation, change management, and stakeholder trust.
- How leading organizations are using AI today: practical examples of AI-driven automation improving efficiency, safety, and decision quality.
Throughout, the emphasis is on automation that respects the quality system. As agents take on more of the workflow, validation thinking shifts toward risk-based approaches like computer software assurance (CSA), so testing effort follows risk rather than treating every step the same.
Who should download it
- Biotech and pharma executives defining AI strategy and operating model priorities.
- Clinical, Regulatory, Quality, and Safety leaders evaluating intelligent workflow opportunities.
- IT, data, and automation teams responsible for AI architecture, governance, integrations, and lifecycle management.
- Compliance and validation teams ensuring AI-supported processes remain explainable, controlled, and inspection-ready.
FAQ: Agentic AI and Intelligent Workflows in Life Sciences
What is agentic AI, and how is it different from traditional automation?
Traditional automation follows predefined rules and stops at the edge of its script. Agentic AI can interpret context, coordinate multiple steps, recommend next actions, trigger supporting workflows, and escalate to a human when judgment or approval is required. That coordination is what makes it useful across fragmented clinical, regulatory, quality, and operational processes where data and accountability live across many systems.
Where can agentic AI add the most value in biotech and pharma?
The white paper points to high-value workflows such as clinical trial operations, predictive safety monitoring, regulatory and submission workflow support, and operational decision-making — anywhere targeted, governed automation can compress cycle time without sacrificing evidence quality.
How do we keep AI-supported workflows compliant in regulated environments?
Design around regulated work from the start: intended use, data provenance, access controls, decision rights, audit trails, model oversight, and validated change. The agent must fit the quality system rather than the other way around. That typically pairs disciplined AI governance with risk-based validation under computer software assurance and 21 CFR Part 11 expectations for electronic records.
What should we measure to know whether an agentic workflow is working?
Track productivity and control performance together — for example, trial workflow cycle time, submission readiness acceleration, exception reduction, and human oversight traceability. If AI makes work faster but less explainable, the program is creating risk, not reducing it.
How do we move from a pilot to a scaled program?
Build the roadmap, data governance, and adoption model needed for durable transformation. That means treating agents as governed, validated systems and supporting them with the human-plus-AI delivery model described in USDM's agentic team approach.
Download the white paper
Get the full guide to applying agentic AI and intelligent workflows across clinical, regulatory, quality, and operations — with the governance, validation, and oversight that regulated work demands. Complete the form to download Reimagining Biotech and Pharma: The Rise of Agentic AI and Intelligent Workflows, or contact USDM to discuss your AI strategy and operating model.